Trials Near Add Your Location
Accepting patients
VMD-928
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
Accepting patients
Larotrectinib
A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Tyrosine Kinase (TK) Inhibitor
- Phase 1
Accepting patients
TRIDENT-1
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
- Has results
Accepting patients
CARE Study
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
- Has results
Accepting patients
NAUTIKA1
NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
- Phase 2
Accepting patients
TL118
A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions
- Tropomyosin Receptor Kinase (TRK) Inhibitor
- Phase 2
Accepting patients
LANTERN
Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions
- Tyrosine Kinase (TK) Inhibitor
- Radiation
- Phase 2
Accepting patients
Avutometinib and Defactinib
Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients
- Focal Adhesion Kinase (FAK) Inhibitor
- MEK Inhibitor
- Phase 2
Accepting patients
Larotrectinib
A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive Tumors
- Tyrosine Kinase (TK) Inhibitor
- Phase 2
Accepting patients
Cabozantinib
A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- Tyrosine Kinase (TK) Inhibitor
- Phase 2
- Has results